Table 2.
Treatment characteristics among breast cancer patients undergoing surgery
| Pre-COVID (N = 356) |
During-COVID (N = 187) |
Total (N = 543) |
p value | |
|---|---|---|---|---|
| Axillary surgery | 0.9501 | |||
| Missing | 0 | 2 | 2 | |
| None | 66 (18.5%) | 33 (17.8%) | 99 (18.3%) | |
| SLN only | 229 (64.3%) | 121 (65.4%) | 350 (64.7%) | |
| SLN + ALND | 37 (10.4%) | 17 (9.2%) | 54 (10.0%) | |
| ALND only | 24 (6.7%) | 14 (7.6%) | 38 (7.0%) | |
| Breast operation | 0.2211 | |||
| Missing | 0 | 2 | 2 | |
| Breast-conserving surgery | 194 (54.5%) | 89 (48.1%) | 283 (52.3%) | |
| Unilateral mastectomy | 36 (10.1%) | 27 (14.6%) | 63 (11.6%) | |
| UM+reconstruction | 36 (10.1%) | 14 (7.6%) | 50 (9.2%) | |
| Bilateral mastectomy | 26 (7.3%) | 12 (6.5%) | 38 (7.0%) | |
| BM+reconstruction | 64 (18.0%) | 43 (23.2%) | 107 (19.8%) | |
| Surgery type | 0.1581 | |||
| Missing | 0 | 2 | 2 | |
| Breast-conserving surgery | 194 (54.5%) | 89 (48.1%) | 283 (52.3%) | |
| Mastectomy | 162 (45.5%) | 96 (51.9%) | 258 (47.7%) | |
| Reconstruction (among mastectomy patients) | 0.7081 | |||
| No reconstruction | 62 (38.3%) | 39 (40.6%) | 101 (39.1%) | |
| Reconstruction | 100 (61.7%) | 57 (59.4%) | 157 (60.9%) | |
| Neoadjuvant therapy | 0.0191 | |||
| No neoadjuvant therapy | 254 (71.3%) | 115 (61.5%) | 369 (68.0%) | |
| Neoadjuvant therapy | 102 (28.7%) | 72 (38.5%) | 174 (32.0%) | |
| Neoadjuvant chemotherapy | 0.7161 | |||
| No neoadjuvant chemotherapy | 279 (78.4%) | 144 (77.0%) | 423 (77.9%) | |
| Neoadjuvant chemotherapy | 77 (21.6%) | 43 (23.0%) | 120 (22.1%) | |
| Neoadjuvant endocrine therapy | 0.0021 | |||
| No neoadjuvant endocrine therapy | 331 (93.0%) | 158 (84.5%) | 489 (90.1%) | |
| Neoadjuvant endocrine therapy | 25 (7.0%) | 29 (15.5%) | 54 (9.9%) |
1Chi-square